Adaptimmune Therapeutics Projects Sarcoma Franchise to Generate up to $400M in Peak Year Sales
🌥️Trending News Adaptimmune Therapeutics ($NASDAQ:ADAP), a clinical-stage biopharmaceutical company focused on developing T-cell therapies to treat cancer, has projected that [...]
ADAPTIMMUNE THERAPEUTICS Reports Third Quarter FY2023 Earnings Results
🌥️Earnings Overview ADAPTIMMUNE THERAPEUTICS ($NASDAQ:ADAP) released their financial report for the third quarter of FY2023, ending on September 30 2023. [...]
Adaptimmune Therapeutics Stock Fair Value Calculation – ADAPTIMMUNE THERAPEUTICS Reports 4.4% Increase in Total Revenue for Q3 FY2023
☀️Earnings Overview For the third quarter of fiscal year 2023, ADAPTIMMUNE THERAPEUTICS ($NASDAQ:ADAP) reported total revenue of USD 7.3 million, [...]
ADAPTIMMUNE THERAPEUTICS Reports Financial Results for Second Quarter of FY2023
🌥️Earnings Overview On June 30, 2023, ADAPTIMMUNE THERAPEUTICS ($NASDAQ:ADAP) released their financial results for the second quarter of the fiscal [...]
ADAPTIMMUNE THERAPEUTICS Reports Second Quarter Earnings for FY2023 on August 9, 2023
🌥️Earnings Overview On August 9, 2023, ADAPTIMMUNE THERAPEUTICS ($NASDAQ:ADAP) released its earnings for the second quarter of fiscal year 2023, [...]
Adaptimmune Therapeutics Merges with TCR2 to Advance Immunology Research
🌥️Trending News Adaptimmune Therapeutics ($NASDAQ:ADAP), a leading firm in the immunology sector, has recently finalized its merger with TCR2, another [...]
Adaptimmune Therapeutics Stock Intrinsic Value – ADAPTIMMUNE THERAPEUTICS Reports Q1 Revenue of $47.6M, Exceeding Street Estimate of $4.6M.
🌥️Trending News ADAPTIMMUNE THERAPEUTICS ($NASDAQ:ADAP), a biopharmaceutical company that focuses on developing engineered T-cell therapies, recently reported its Q1 revenue [...]
Adaptimmune Therapeutics Intrinsic Value – Adaptimmune Therapeutics Reports 14-Cent EPS Beat on $47.6M Revenue
Trending News 🌥️ The company exceeded expectations by achieving a GAAP earnings per share of $0.14 and total revenue of [...]
Adaptimmune Therapeutics Intrinsic Value – Comparing the Potential of Axcella Health and Adaptimmune Therapeutics in the Biotech Industry
Trending News 🌥️ Adaptimmune's lead product candidate is its NY-ESO TCR (T-cell receptor), which is designed to target and attack [...]
Adaptimmune Therapeutics Stock Intrinsic Value – Adaptimmune Therapeutics PLC – ADR Plummets 21.82% in One Week, Is it Time to Buy?
Trending News 🌥️ Adaptimmune Therapeutics ($NASDAQ:ADAP) PLC - ADR has seen a sharp decrease in its stock price of -21.82% [...]
